Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that biopharmaceutical industry veteran William Hodder has joined the company as Vice President of Business Development. Mr. Hodder will be responsible for leading the Promedior’s business development activities as its lead drug candidates targeting fibrosis continue to advance through clinical development for serious and life threatening fibrotic diseases, including myelofibrosis and idiopathic pulmonary fibrosis (IPF).